Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 33863 - trabeculated knee femur prosthesis - femoral component of a constrained knee replacement prosthesis. composed of cocrmo coated with tin. connects to various femoral stems as part of a modular universal tumour and revision system (mutars). a component of the mutars system intended to replace the femoral articulating surfaces of the knee. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 32831 - uncoated knee femur prosthesis - femoral component of a constrained knee replacement prosthesis. composed of cocrmo coated with tin. connects to various femoral stems as part of a modular universal tumor and revision system (mutars. a component of the mutars system intended to replace the femoral articulating surfaces of the knee. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 48088 - humeral head prosthesis - humeral head replacement prosthesis. composed of tial6v4. connects to a humerus cap and extension piece as part of a proximal or total humeral replacement in a modular universal tumor and revision system (mutars). a component of the mutars system intended to replace the humeral head as part of a proximal or total humerus reconstruction. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 33178 - revision uncoated hip femur prosthesis - prosthesis to replace the metaphyseal section of the femur. composed of tial6v4. connects to a proximal femoral component and extension piece or stem as part of hip revision or total femoral replacement in a modular universal tumor and revision system (mutars). a component of the mutars system intended to replace the metaphyseal part of the proximal femur. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 33714 - body femoral extension - prosthesis to replace the metaphyseal section of the femur. composed of tial6v4 coated with hydroxyapatite. connects to a proximal femoral component and extension piece or stem as part of hip revision or total femoral replacement in a modular universal tumor and revision system (mutars). a component of the mutars system intended to replace the metaphyseal part of the proximal femur. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis.

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - Офталмологични - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.

Kesatuan Eropah - Norway - EMA (European Medicines Agency)

santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - Øyemidler - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

santen sa - netarsudilum, latanoprostum - collyre en solution - netarsudilum 0.2 mg ut netarsudili dimesilas, latanoprostum 0.05 mg, mannitolum, acidum boricum, benzalkonii chloridum 0.2 mg, natrii hydroxidum ad ph, aqua ad iniectabile ad solutionem pro 1 ml. - glaucome à angle ouvert, hypertension oculaire - synthetika

Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

santen oy - netarsudil - glaucoma, open-angle; ocular hypertension - Офталмологични - Намаляване на повишено вътреочното налягане (ВОН) при възрастни пациенти с първична откритоъгълна глаукома или очна хипертония.